Anixa Biosciences, Inc. (ANIX) financial statements (2022 and earlier)

Company profile

Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE, CA 95118
State of Incorp. DE
Fiscal Year End October 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

1/31/2022
TTM
10/31/2021
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:34,53035,7289,0575,8425,0566,8393,238
Cash and cash equivalents29,78129,1286,4173,4923,0563,3392,488
Short-term investments4,7496,6002,6402,3502,0003,500750
Other undisclosed cash, cash equivalents, and short-term investments    0(0)(0)
Receivables  267   
Other undisclosed current assets464276309185482175162
Total current assets:34,99436,0039,3696,0935,5387,0143,400
Noncurrent Assets
Operating lease, right-of-use asset24425454 
Property, plant and equipment   2017353157
Intangible assets, net (including goodwill)   (2,034)(1,616)(1,290)(965)
Intangible assets, net (excluding goodwill)   (2,034)(1,616)(1,290)(965)
Other undisclosed noncurrent assets  302,0342,4533,0363,036
Total noncurrent assets:244254842019101,7982,228
TOTAL ASSETS:35,23836,2579,4536,2946,4498,8125,628
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,7461,2311,1331,4811,265889469
Accounts payable504136232586582480373
Accrued liabilities1,2421,09590189568340946
Employee-related liabilities      50
Other undisclosed current liabilities413955    
Total current liabilities:1,7871,2711,1891,4811,265889469
Noncurrent Liabilities
Long-term debt and lease obligation209220     
Operating lease, liability209220  
Other undisclosed noncurrent liabilities(209)(220)    4,172
Total noncurrent liabilities:209220    4,172
Total liabilities:1,9961,4911,1891,4811,2658894,641
Stockholders' equity
Stockholders' equity attributable to parent33,96335,4378,7615,2355,4357,923987
Preferred stock      14
Common stock30130124220318916688
Additional paid in capital242,281239,927200,354186,849175,416163,931152,051
Accumulated deficit(208,619)(204,790)(191,836)(181,817)(170,170)(156,174)(151,165)
Stockholders' equity attributable to noncontrolling interest(721)(671)(497)(423)(251)  
Total stockholders' equity:33,24234,7678,2644,8125,1837,923987
TOTAL LIABILITIES AND EQUITY:35,23836,2579,4536,2946,4498,8125,628

Income statement (P&L) ($ in thousands)

1/31/2022
TTM
10/31/2021
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
Revenues513513 2501,113363300
Revenue, net 300
Cost of revenue(4,755)(990)(4,381)(51)(1,984)(249)(398)
Gross profit:(4,242)(478)(4,381)199(871)113(98)
Operating expenses(10,027)(12,658)(5,597)(12,089)(13,418)(6,189)(4,411)
Other undisclosed operating loss(513)      
Operating loss:(14,783)(13,136)(9,978)(11,890)(14,289)(6,076)(4,509)
Nonoperating income
(Investment Income, Nonoperating)
   71461913
Interest and debt expense     1,047(520)
Loss before gain (loss) on sale of properties:(14,783)(13,136)(9,978)(11,819)(14,243)(5,009)(5,016)
Other undisclosed net income (loss)88(114)    
Net loss:(14,775)(13,128)(10,092)(11,819)(14,243)(5,009)(5,016)
Net income attributable to noncontrolling interest19917474172247  
Other undisclosed net loss attributable to parent     (2,009) 
Net loss available to common stockholders, diluted:(14,575)(12,954)(10,018)(11,647)(13,996)(7,018)(5,016)

Comprehensive Income ($ in thousands)

1/31/2022
TTM
10/31/2021
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
Net loss:(14,775)(13,128)(10,092)(11,819)(14,243)(5,009)(5,016)
Comprehensive loss:(14,775)(13,128)(10,092)(11,819)(14,243)(5,009)(5,016)
Comprehensive income, net of tax, attributable to noncontrolling interest19917474172247  
Comprehensive loss, net of tax, attributable to parent:(14,575)(12,954)(10,018)(11,647)(13,996)(5,009)(5,016)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: